Skip to main content

Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Immunic Inc (NASDAQ: IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).

Dr Vitt explains that 467 patients have been enrolled across various sub-indications including primary progressive, secondary active, and non-active secondary progressive MS. He calls it a "great day for the programme." The trial aims to assess the efficacy of IMU-838 and Dr. Vitt highlights the focus on biomarkers, particularly the neurofilament light chain (NFL), a protein indicative of active disease.

Anticipated next steps include an interim analysis set for release this fall, which will examine biomarker benefits for different sub-indications. Dr. Vitt also reflects on what he considers a successful 2023 so far, with positive data emerging from Immunic's colitis maintenance and IMU-856 celiac disease programs.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-ceo-hails-great-day-after-completing-imu-838-phase-2-trial-enrolment-801372157

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.82
-10.55 (-4.10%)
AAPL  342.56
-6.65 (-1.90%)
AMD  424.39
-64.80 (-13.25%)
BAC  47.04
-1.53 (-3.15%)
GOOG  264.00
-7.02 (-2.59%)
META  560.84
-35.38 (-5.93%)
MSFT  484.52
-13.78 (-2.77%)
NVDA  125.53
-20.45 (-14.01%)
ORCL  101.19
-9.38 (-8.48%)
TSLA  345.82
-28.59 (-7.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.